



ABIVAX to present at the BIO Europe 2015 conference and at the Deutsches Eigenkapitalforum

Paris, October 15, 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a publicly traded, clinical stage biotech company developing and commercializing therapeutic anti-viral drugs and vaccines, today announced the participation of its CEO, Prof. Dr. Hartmut Ehrlich, at the BIO Europe 2015 conference, to be held in Munich on November 2nd to 4th, and at the Deutsches Eigenkapitalforum to be held in Frankfurt on November 23rd and 24th. Prof. Ehrlich will make presentations on ABIVAX's current development program and strategy at both events as follows:

- November 3rd at 5:00 PM at the BIO Europe 2015 conference in Munich
- November 23rd at 3:30 PM at the Deutsches Eigenkapitalforum in Frankfurt

About ABIVAX

ABIVAX is an advanced clinical development biotech company focused on becoming a global leader in the discovery, development and commercialization of therapeutic anti-viral drugs and vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B.

ABIVAX has 2 compounds in clinical stage research: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic Hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months.

ABX464 has been developed using ABIVAX's anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients' clear important pathogenic viruses.

Headquartered in Paris, France, ABIVAX conducts its research and development in Montpellier and Évry (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS--Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy.

ABIVAX was founded by Dr. Philippe Pouletty, M.D., managing partner at Truffle Capital, the cornerstone investor in ABIVAX. The company is listed on the regulated market of Euronext Paris, compartment B (ISIN code: FR0012333284 – Ticker: ABVX). For more information, please visit www.abivax.com. Follow us on Twitter @ABIVAX_

Contacts

Prof. Hartmut J. Ehrlich, M.D., CEO of ABIVAX

Investor relations

Raquel Lizarraga
raquel.lizarraga@abivax.com

Press relations

ALIZE RP
Caroline Carmagnol and Florence
Portejoie

+33 1 53 83 06 93

abivax@alizerp.c
om
+33 6 64 18 99 59 / + 33 1 44 54
36 64